IN8bio has announced that preclinical data for its gamma-delta CAR-T technology, INB-300, will be presented at the American Association for Cancer Research, AACR, Annual Meeting 2023. The event will be held in Orlando, Florida, from April 14-19. IN8bio’s non-signaling CAR platform is based on the natural innate immune recognition of gamma-delta T cells. By using a CAR that lacks a CD3z signaling domain, IN8bio believes it has created a technology that enables these cells to differentiate between tumor and healthy tissue, even when both express the CAR-targeted antigen. IN8bio is not seeking to advance this construct into the clinic but the data to be presented includes a proof-of-concept study against the validated target of CD19. "We are thrilled to present promising preclinical data from our next-generation CAR platform, which shows the potential of INB-300 to differentiate between cancerous and healthy tissue," said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer of IN8bio. "Our goal is to improve upon existing technologies with a targeted and potentially less toxic approach for patients who require more innovative therapies. We are encouraged by these results and look forward to further evaluating nsCAR programs in additional promising targets such as CD33 for acute myeloid leukemia."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INAB:
